Andrew Komjathy
Corporate Officer/Principal at ASTRIA THERAPEUTICS, INC.
Net worth: 1 408 $ as of 2024-03-30
Profile
Andrew A.
Komjathy is currently the Chief Commercial Officer at Astria Therapeutics, Inc. Prior to this, he was the Vice President-Commercial Sales at Alkermes, Inc. from 2014 to 2018, the VP-U.S.
Multiple Sclerosis Business Unit Sales at Genzyme Corp.
from 2012 to 2014, and the VP & GM-North American Commercial Operations at Shire Human Genetic Therapies, Inc. from 2005 to 2012.
Mr. Komjathy received his undergraduate degree from Bucknell University and his MBA from The Leonard N Stern School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-07 | 100 ( 0.00% ) | 1 408 $ | 2024-03-30 |
Andrew Komjathy active positions
| Companies | Position | Start |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-09-24 |
Former positions of Andrew Komjathy
| Companies | Position | End |
|---|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Sales & Marketing | 2018-10-31 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Sales & Marketing | 2013-12-31 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 2011-12-31 |
Training of Andrew Komjathy
| Bucknell University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Andrew Komjathy
